Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228304 · ClinicalTrials.gov registry record · Phase 1
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
A Phase 1 study, sponsored by Neurotech Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02228304 is a Phase 1 study that was terminated before completion, run by Neurotech Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT02228304, a Phase 1 study, was terminated before completion, sponsored by Neurotech Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those who, in the opinion of the investigator, are still candidates for continued anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate, randomized, masked phase during which eligible patients will be randomized to the NT-503-3 group or the control group. Clinical Hypotheses: * NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the prevention of vision loss due to recurrent CNV secondary to AMD * NT-503-3 ECT has an acceptable safety profile
Interventions
- DRUG NT-503-3 ECT implantation
- DRUG Eylea® injected intravitreally administered every 8 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228304
The ClinicalTrials.gov registry entry for NCT02228304 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NT-503-3 ECT implantation is the first listed.
NCT02228304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228304 about?
NCT02228304 is a clinical study titled "Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)". Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those who, in the opinion of the investigator, are still candidates for continued anti-VEGF therapy will b...
What is the current status of trial NCT02228304?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2014-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02228304?
The interventions under investigation include: NT-503-3 ECT implantation (DRUG), Eylea® injected intravitreally administered every 8 weeks (DRUG).
Who is sponsoring clinical trial NCT02228304?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.